文献速递前列腺癌

根治性前列腺切除术后高危前列腺癌患者基线健康相关生活质量对生存预测的附加价值

The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy.
PubMed 文献 · J Urol · 2022-07-05

本研究纳入1029例高危前列腺癌患者,前瞻性评估根治性前列腺切除术前基线健康相关生活质量。多变量分析显示基线总体健康状况是生化复发无生存和转移无生存的独立预测因子,加入模型可提高预测准确性并在所有阈值概率下显示净获益。

要点

  • 基线总体健康状况是生化复发无生存的独立预测因子(HR 0.97,95%CI 0.96-0.99;P=0.001)。
  • 基线总体健康状况是转移无生存的独立预测因子(HR 0.96,95%CI 0.93-0.99;P=0.013)。
  • 将基线健康相关生活质量加入模型可提高对生化复发无生存和转移无生存的预测准确性。

核心结论

  • 基线健康相关生活质量是局限性高危前列腺癌患者根治性前列腺切除术前一个有价值且稳健的预后因素。
  • 基线健康相关生活质量提高了生化复发无生存和转移无生存的预测准确性。

研究设计与样本

  • 研究纳入1029例根据美国国家综合癌症网络(NCCN)风险分层为高危前列腺癌并在根治性前列腺切除术前前瞻性评估基线健康相关生活质量的患者。
  • 患者按QLQ-C30问卷的总体健康状况领域进行分层。
  • 肿瘤学终点为生化复发无生存和转移无生存。
  • 采用多变量Cox回归模型评估基线总体健康状况对生存结局的预后意义。
  • 应用Harrell判别C指数计算模型及既往风险分层模型的预测准确性,并应用决策曲线分析检验将总体健康状况加入多变量模型的临床净获益(P<0.05)。

主要发现

  • 中位随访43个月。
  • 多变量分析证实总体健康状况是生化复发无生存提高的独立预测因子(HR 0.97,95%CI 0.96-0.99;P=0.001)。
  • 多变量分析证实总体健康状况是转移无生存提高的独立预测因子(HR 0.96,95%CI 0.93-0.99;P=0.013)。
  • 基线总体健康状况每增加1分,生化复发无生存的相对风险降低2.9%,转移无生存的相对风险降低3.7%。
  • 将基线健康相关生活质量加入模型以及前列腺癌风险评估(CAPRA)和NCCN评分,改善了各模型对生化复发无生存和转移无生存的判别能力。

关键数值与推荐

  • 高危前列腺癌根据NCCN风险分层定义。
  • 基线健康相关生活质量采用QLQ-C30问卷总体健康状况领域评估。
  • 生化复发无生存的独立预测因子HR 0.97(95%CI 0.96-0.99;P=0.001)。
  • 转移无生存的独立预测因子HR 0.96(95%CI 0.93-0.99;P=0.013)。
  • 基线总体健康状况每增加1分,生化复发无生存相对风险降低2.9%,转移无生存相对风险降低3.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Several studies have shown baseline health-related quality of life to be a valuable prognostic indicator of survival outcomes for various cancer entities in the metastatic setting. To date, there is no evidence regarding the prognostic value of baseline health-related quality of life for patients undergoing radical prostatectomy due to localized prostate cancer. MATERIALS AND METHODS: A total of 1,029 patients with high-risk prostate cancer according to National Comprehensive Cancer Network® risk stratification and prospectively assessed baseline health-related quality of life prior to radical prostatectomy were identified. Patients were stratified by global health status domain of the QLQ-C30 questionnaire. Oncologic endpoints were biochemical recurrence-free survival and metastasis-free survival. Multivariable Cox regression models were performed to assess prognostic significance of baseline global health status on survival outcomes. Harrell's discrimination C-index was applied to calculate the predictive accuracy of the model and previously described risk stratification models. Decision curve analysis was applied to test the clinical net benefit associated with adding global health status to our multivariable model (P < .05). RESULTS: Median follow-up was 43 months. In multivariable analysis, global health status was confirmed as an independent predictor for increased biochemical recurrence-free survival (HR .97, 95% CI .96-.99; P = .001) and metastasis-free survival (HR .96, 95% CI .93-.99; P = .013), indicating a relative risk reduction of 2.9% for biochemical recurrence-free survival and 3.7% for metastasis-free survival per 1-point increase of baseline global health status. Adding baseline health-related quality of life to our model and to the Cancer of the Prostate Risk Assessment and National Comprehensive Cancer Network score improved discrimination in predicting biochemical recurrence-free survival and metastasis-free survival of the respective models. Decision curve analysis revealed a net benefit over all threshold probabilities. CONCLUSIONS: Our findings highlight baseline health-related quality of life to be a valuable and robust prognostic factor for patients with localized high-risk prostate cancer prior to radical prostatectomy. Baseline health-related quality of life increased prognostic accuracy of biochemical recurrence-free survival and metastasis-free survival.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Westhofen T, Buchner A, Kasivisvanathan V, et al. The Added Value of Baseline Health-Related Quality of Life in Predicting Survival in High-Risk Prostate Cancer Patients Following Radical Prostatectomy. J Urol. 2022. PMID: 35830558. doi:10.1097/JU.0000000000002826

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。